Loading stock data…
Denali Therapeutics Inc. (DNLI)
$25.89+0.32 (+1.25%)
Market ClosedLast close Jun 29
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Denali Therapeutics Inc. in the Healthcare sector is trading at $25.89 with a market capitalization of $3.1B. Wall Street consensus targets $33.93 (15 analysts), implying a +31.1% move over the next 12 months. The stock is currently near its 52-week high of $26.19, remaining 38.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +31.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$137.36M | -$137.37M | -$137.43M↓ | -$134.96M↑ | -$145.58M |
| Net Income | -$128.45M | -$128.55M↓ | -$126.90M↓ | -$124.12M↑ | -$132.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflamma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.86%
Volume
Today's trading volume
2.13M
Recent News
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Pfizer CFO to step down; Denali sells a regulatory fast-pass
A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid dividends.
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease
By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part of a previously signed agreement, it stated. Register for our weekly newsletter HERE “We are […] The post Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease appeared first on ExecEdge.
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best AI driven biotech stocks to invest in. On May 22, Denali Therapeutics Inc. (NASDAQ:DNLI) halted its joint work with Biogen Inc. (NASDAQ:BIIB), around the development of BIIB122 for idiopathic Parkinson’s disease. The decision came after topline results from the Phase 2b LUMA trial showed that […]